other dosage forms:
needed effects
vancomycin
unwanted side effects
medical attention
following side effects
taking vancomycin
check
doctor
vancomycin side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
renal side effects
nephrotoxicity
increased serum creatinine
bun concentrations
large doses
rare cases of renal failure
interstitial nephritis
tubulointerstitial nephritis
abnormal renal function
azotemia
risk of nephrotoxicity
vancomycin trough levels
exceeding mcg/ml
nephrotoxicity
renal failure
renal impairment
increased blood creatinine
patients
oral formulation
nephrotoxicity
marketed formulation of vancomycin
potential for nephrotoxicity
current formulation
unusual cases of acute interstitial nephritis
rash
eosinophilia
fever
acute tubulointerstitial nephritis
fatal toxic epidermal necrolysis
nephrotoxicity
following oral vancomycin
week after therapy completion
median day of onset
day
nephrotoxicity
following oral vancomycin
patients
years of age
patients years of age
nervous system
side effects
ototoxicity
tinnitus
sensorineural hearing loss in association with elevated vancomycin serum concentrations
hearing loss
lethargy
headache
dizziness
orthostatic syncope
confusion
case of neuralgic amyotrophy
case of mononeuritis
vancomycin therapy
headache
insomnia
oral formulation
cases of hearing loss
intravenous vancomycin
postmarketing experience
patients with kidney dysfunction
preexisting hearing loss
receiving
receiving concurrent treatment with an ototoxic drug
vertigo
dizziness
tinnitus
postmarketing experience
ototoxicity
marketed formulation of vancomycin
potential for ototoxicity
current formulation
bilateral sensorineural hearing loss
year-old male
following administration
mg
intrathecal doses of vancomycin in addition
intravenous vancomycin
patient
headaches
dizziness
orthostatic syncope
lethargy
incidence of insomnia
oral formulation
patients
years of age
patients years of age
hematologic side effects
reversible neutropenia
rare cases of thrombocytopenia
anemia
reversible agranulocytosis
granulocytes
mm
leukopenia
anemia
oral formulation
thrombocytopenia
reversible neutropenia
intravenous vancomycin
eosinophilia
vancomycin administration
postmarketing experience
reversible neutropenia
week
onset of intravenous vancomycin therapy
total dose of more than g.
neutropenia
vancomycin
vancomycin
antineutrophilic antibodies
year-old male developed neutropenia
positive antineutrophilic antibodies after days of vancomycin
wbc
cells/mm
discontinuation of vancomycin
initiation of granulocyte-colony stimulating factor
thrombocytopenia with a positive rechallenge
chronic osteomyelitis
vancomycin
g
hours
g
hours by hospital day platelet count
mm
days before initiation of vancomycin
mm after days of therapy
hospital day
vancomycin
platelets
mm by day
vancomycin on day
prompt decrease in platelet count
mm
days
platelet count
couple days after discontinuation of vancomycin
patient
surgery
trimethoprim/sulfamethoxazole
mechanism of vancomycin-induced thrombocytopenia
direct toxic effect
other concurrent medications
causative agents
spontaneous reports of thrombocytopenia
vancomycin
manufacturer
study
n =-rrb-
thrombocytopenia
platelets
l
patients
severe thrombocytopenia
platelets
l
receiving vancomycin for more than days
incidence of anemia
oral formulation
patients
years of age
patients years of age
intraperitoneal administration of sterile vancomycin during continuous ambulatory peritoneal dialysis
chemical peritonitis
cloudy dialysate
abdominal pain
fever
discontinuation of intraperitoneal vancomycin
incidences
vomiting
constipation
oral formulation
patients
years of age
patients years of age
common side effects
discontinuation of oral vancomycin
nausea
vomiting
clostridium difficile colitis
gastrointestinal side effects
injectable formulation
clostridium difficile
associated diarrhea
chemical peritonitis
following
following intraperitoneal administration
pseudomembranous colitis
nausea
abdominal pain
vomiting
diarrhea
flatulence
constipation
clostridium difficile colitis
oral formulation
nausea
vancomycin administration
postmarketing experience
other side effects
infusion-related events
drug-induced fever
chills
red man syndrome
infusion-related events
rapid infusion of vancomycin
symptoms
anaphylactoid reactions
including hypotension
wheezing
dyspnea
urticaria
pruritus
flushing of the upper body
red neck
pain
muscle spasm of the chest
pyrexia
peripheral edema
fatigue
oral formulation
condition
intravenous-induced syndrome
postmarketing experience with oral vancomycin
symptoms
anaphylactoid reactions
including hypotension
wheezing
dyspnea
urticaria
pruritus
flushing of the upper body
red man syndrome
pain
muscle spasm of the chest
drug fever
chills
vancomycin administration
postmarketing experience
infusion of vancomycin over less than minutes
increased incidence of red man syndrome
slowing
infusion rate
syndrome
pretreatment with antihistamines
increased patient tolerance
red man syndrome
nonspecific release of histamine
allergic reaction
anaphylactoid reactions
minutes
several hours
incidence of peripheral edema
oral formulation
patients
years of age
patients years of age
incidence of hypokalemia
oral formulation
patients
years of age
patients years of age
metabolic side effects
oral formulation
hypokalemia
local side effects
extravasation
administered vancomycin
pain
tenderness
necrosis
phlebitis
inflammation at the injection site
thrombophlebitis
nonbullous vancomycin-induced skin necrosis
incidence of hypotension
oral formulation
patients
years of age
patients years of age
cardiovascular
side effects
phlebitis
vasculitis
rare cases of dose-dependent hypotension
lupus-like vasculitis
leukocytoclastic vasculitis
case of cardiac arrest
rapid infusion of vancomycin therapy
g
minutes
hypotension
oral formulation
vasculitis
vancomycin administration
postmarketing experience
musculoskeletal side effects
severe chest
shoulder
low back pains during intravenous administration of vancomycin in patients
undergoing peritoneal dialysis
pain
oral formulation
hypersensitivity side effects
erythema multiforme
exfoliative dermatitis
linear iga
bullous dermatosis
stevens-johnson syndrome
anaphylaxis
drug rash with eosinophilia
systemic symptoms
dress syndrome
intravenous vancomycin
postmarketing experience
anaphylaxis
vancomycin administration
postmarketing experience
erythematous rash after days of treatment with vancomycin
piperacillin
tazobactam
ciprofloxacin
rash
skin sloughing
body
including
oral mucosa
palms
soles
genitals
conjunctiva
days after onset
skin biopsies
direct immunofluorescence
diagnosis of linear iga
bullous dermatosis
cases of vancomycin-associated linear iga
bullous dermatosis
mucosa
conjunctiva
dermatologic side effects
rash
exfoliative dermatitis
stevens-johnson syndrome
toxic epidermal necrolysis
bullous skin disease
fatalities
case of acute tubulointerstitial nephritis
fatal toxic epidermal necrolysis
rashes
including
exfoliative dermatitis
stevens-johnson syndrome
toxic epidermal necrolysis
vancomycin administration
postmarketing experience
incidence of depression
oral formulation
patients
years of age
patients years of age
psychiatric side effects
oral formulation
depression
genitourinary side effects
oral formulation
urinary tract infection
incidence of urinary tract infection
oral formulation
patients
years of age
patients years of age
year-old male with clostridium
difficile-associated enterocolitis
oral vancomycin because diarrhea
metronidazole
patient
diarrhea
day of oral vancomycin treatment
patient
alt
ast
vancomycin
days of vancomycin discontinuation
patient
alt
ast levels
patient
total of courses of oral vancomycin
diarrhea
course of oral vancomycin
patient
alt
ast levels
normal following discontinuation of the drug
following
discontinuation of the final course of oral vancomycin
patient
c
difficile-associated enterocolitis
liver enzyme levels
hepatic side effects
elevated aspartate transaminase
ast
alanine transaminase
alt
oral vancomycin
case report
abnormal liver function
intravenous administration
respiratory side effects
case of interstitial pneumonia
side effects of vancomycin
fda
healthcare professional for medical advice
intravenous powder for solution
intravenous solution
bladder pain
bloating
swelling of the face
arms
hands
lower legs
feet
cloudy urine
convulsions
decreased urine
burning
painful urination
dry mouth
fever
frequent urge
increased thirst
irregular heartbeat
loss of appetite
side pain
mood changes
muscle pain
cramps
nausea or vomiting
numbness
tingling in the hands
feet
lips
rapid weight gain
shortness of breath
unusual tiredness
weakness
unusual weight gain
loss
change in the frequency of urination
amount of urine
difficulty with breathing
drowsiness
weakness
hives
redness
other discoloration of the skin
scaling
welting of the skin
skin rash
black, tarry stools
bleeding gums
blistering
peeling
loosening of the skin
blurred vision
chills
confusion
continuing ringing
buzzing
other unexplained noise in the ears
cough
diarrhea
difficulty with swallowing
dizziness
faintness
lightheadedness
getting
lying
sitting position
fast heartbeat
feeling of constant movement of self
surroundings
feeling of fullness in the ears
hearing loss
itching
muscle pain
loss of balance
side pain
pale skin
red spots on the skin
puffiness
swelling of the eyelids
eyes
face
lips
tongue
red skin lesions
purple center
red, irritated eyes
ringing
buzzing in the ears
sensation of spinning
sore throat
sores
ulcers
white spots in the mouth
lips
sweating
tightness in the chest
troubled breathing with exertion
unusual bleeding
bruising
stomach pain
back pain
unpleasant taste
excess air
gas in the stomach
intestines
headache
mouth irritation
passing gas
depression
difficulty
bowel movement
stool
trouble sleeping